NYSE American: IGC

Investor Relations

Lorem ipsum dolor sit amet consectetur. In commodo dictumst tempus ac mauris. Augue nisi porttitor sapien malesuada proin. Mauris lacinia consectetur vitae scelerisque vitae. Aliquet egestas et egestas gravida elit id molestie. Amet.

Explore Our Deck

Find the company overview and discover with us exciting scientific developments and business opportunities.

Read More

Download Our Annual Report

Lorem ipsum dolor sit amet consectetur. In commodo dictumst tempus ac mauris. Augue nisi porttitor sapien malesuada proin

Download Report

Latest News

IGC Pharma Expands Phase 2 CALMA Trial into Colombia’s Premier Alzheimer’s Research Center 

February 9, 2026

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation 

February 2, 2026

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trail Site at Integrative Clinical Trials in New York 

January 22, 2026

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship network site, in Richmond, Virginia 

January 12, 2026
View All

SEC Filings

IGC Pharma, Inc. 424B5 01-06-26

January 6, 2026

IGC Pharma, Inc 8-K 01-06-26

January 6, 2026

IGC Pharma, Inc 8-K 01-02-26

January 2, 2026

IGC Pharma, Inc 8-K 12-15-25

December 15, 2025
View All

Key Reasons

to Invest

Lorem ipsum dolor sit amet consectetur. In commodo dictumst tempus ac mauris. Augue nisi porttitor sapien malesuada proin. Mauris lacinia consectetur vitae scelerisque vitae. Aliquet egestas et egestas gravida elit id molestie. Amet.

Read More

Our Research

IGC-AD1

Lorem ipsum dolor sit amet consectetur. In commodo dictumst tempus ac mauris. Augue nisi porttitor sapien malesuada proin. Mauris lacinia consectetur vitae scelerisque vitae. Aliquet egestas et egestas gravida elit id molestie. Amet.
Learn more

CALMA

Lorem ipsum dolor sit amet consectetur. In commodo dictumst tempus ac mauris. Augue nisi porttitor sapien malesuada proin. Mauris lacinia consectetur vitae scelerisque vitae. Aliquet egestas et egestas gravida elit id molestie. Amet.
Learn more

TGR-63

Lorem ipsum dolor sit amet consectetur. In commodo dictumst tempus ac mauris. Augue nisi porttitor sapien malesuada proin. Mauris lacinia consectetur vitae scelerisque vitae. Aliquet egestas et egestas gravida elit id molestie. Amet.
Learn more

A.I.

Lorem ipsum dolor sit amet consectetur. In commodo dictumst tempus ac mauris. Augue nisi porttitor sapien malesuada proin. Mauris lacinia consectetur vitae scelerisque vitae. Aliquet egestas et egestas gravida elit id molestie. Amet.
Learn more